Cancer is one of the most fatal diseases of recent times that causes several deaths every
year. The disease variations in different parts of the world, the impact of available medical …

In this review, we highlight the role of intratumoral heterogeneity, focusing on the clinical and
biological ramifications this phenomenon poses. Intratumoral heterogeneity arises through …

Growing evidence suggests that aberrant epigenetic regulation of gene function is strongly
related to the genesis of cancer. Unlike genetic mutations, the ability to reprogram the …

The tremendous clinical success of checkpoint blockers illustrates the potential of
reestablishing latent immunosurveillance for cancer therapy. Although largely neglected in …

The acquisition of cancer hallmarks requires molecular alterations at multiple levels
including genome, epigenome, transcriptome, proteome, and metabolome. In the past …

A wide spectrum of metabolites (mainly, the three major nutrients and their derivatives) can
be sensed by specific sensors, then trigger a series of signal transduction pathways and …

Traditionally, intertumour heterogeneity in breast cancer has been documented in terms of
different histological subtypes, treatment sensitivity profiles, and clinical outcomes among …

Cancer is the second leading cause of death globally, trailing only heart disease. In the
United States alone, 1.9 million new cancer cases and 609,360 deaths were recorded for …

Recent studies across multiple tumour types are starting to reveal a recurrent regulatory
architecture in which genomic alterations cluster upstream of functional master regulator …

Nanoparticles promise to improve the treatment of cancer through their increasingly
sophisticated functionalisations and ability to accumulate in certain tumours. Yet recent work …